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The identification of mutations in the Tau gene in frontotemporal
dementia and parkinsonism linked to chromosome 17 (FTDP-
17) has made it possible to express human tau protein with
pathogenic mutations in transgenic animals. Here we report on
the production and characterization of a line of mice transgenic
for the 383 aa isoform of human tau with the P301S mutation.
At 5–6 months of age, homozygous animals from this line
developed a neurological phenotype dominated by a severe
paraparesis. According to light microscopy, many nerve cells in
brain and spinal cord were strongly immunoreactive for hyper-
phosphorylated tau. According to electron microscopy, abun-
dant filaments made of hyperphosphorylated tau protein were
present. The majority of filaments resembled the half-twisted
ribbons described previously in cases of FTDP-17, with a mi-
nority of filaments resembling the paired helical filaments of
Alzheimer’s disease. Sarkosyl-insoluble tau from brains and
spinal cords of transgenic mice ran as a hyperphosphorylated
64 kDa band, the same apparent molecular mass as that of the
383 aa tau isoform in the human tauopathies. Perchloric acid-
soluble tau was also phosphorylated at many sites, with the
notable exception of serine 214. In the spinal cord, neurode-
generation was present, as indicated by a 49% reduction in the
number of motor neurons. No evidence for apoptosis was
obtained, despite the extensive colocalization of hyperphos-
phorylated tau protein with activated MAP kinase family mem-
bers. The latter may be involved in the hyperphosphorylation
of tau.
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Abundant filaments made of hyperphosphorylated microtubule-
associated protein tau constitute a defining characteristic of a
number of neurodegenerative diseases, including Alzheimer’s
disease, Pick’s disease, progressive supranuclear palsy, cortico-
basal degeneration, and frontotemporal dementia and parkinson-
ism linked to chromosome 17 (FTDP-17) (Lee et al., 2001). The
discovery of coding region and intronic mutations in the Tau gene
in FTDP-17 has firmly established that dysfunction of tau protein
can cause neurodegeneration and dementia (Hutton et al., 1998;
Poorkaj et al., 1998; Spillantini et al., 1998a).
In adult human brain, six tau isoforms are expressed from a
single gene by alternative mRNA splicing (Goedert et al., 1988,
1989a,b; Andreadis et al., 1992; Poorkaj et al., 2001). They differ
by the presence or absence of 29 and 58 aa inserts located in the
N-terminal half and an additional 31 aa insert located in the
C-terminal half. Inclusion of the latter, which is encoded by exon
10 of the Tau gene, gives rise to the three isoforms with four
microtubule-binding repeats each. The other three isoforms have
three repeats each. In normal brain, similar levels of three-repeat
and four-repeat tau isoforms are expressed (Goedert and Jakes,
1990). Known mutations in the Tau gene in FTDP-17 are either
missense, deletion, and silent mutations in the coding region or
intronic mutations located close to the splice donor site of the
intron after exon 10. Functionally, they lead to a reduced ability
of tau to interact with microtubules and/or a change in the ratio
of three-repeat to four-repeat tau isoforms, resulting in the rela-
tive overproduction of four-repeat tau (Hasegawa et al., 1998;
Hong et al., 1998; Hutton et al., 1998; Spillantini et al., 1998a;
Yoshida et al., 2002). Some coding region mutations also promote
the assembly of tau protein into filaments (Goedert et al., 1999;
Nacharaju et al., 1999). In FTDP-17, the age of onset of disease
varies, depending on the Tau mutation. The same is true of the
magnitude of the functional effects produced by individual mu-
tations.
Mutation P301S in exon 10 of Tau causes an early onset of
clinical signs and has strong functional effects, as evidenced by a
reduced ability of mutant tau protein to promote microtubule
assembly and a marked stimulatory effect on tau filament assem-
bly (Bugiani et al., 1999; Goedert et al., 1999; Sperfeld et al., 1999;
Yasuda et al., 2000; Morris et al., 2001). Here we describe the
production and characterization of a line of transgenic mice that
express, under the control of the murine thy1 promoter, the 383
aa isoform of human tau with the P301S mutation. At 5–6 months
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of age, homozygous animals developed motor symptoms charac-
terized by a severe paraparesis. Brain and spinal cord contained
insoluble hyperphosphorylated tau protein that migrated on gels
at the same position as filamentous tau from human tauopathies.
By electron microscopy, abundant tau filaments were found. In
the spinal cord, neurodegeneration was present, as evidenced by
a significant reduction in the number of motor neurons.
MATERIALS AND METHODS
Antibodies. A panel of anti-tau antibodies was used (Fig. 1). Antiserum
BR133 recognizes the N terminus of tau; antiserum BR135 is directed
against the microtubule-binding repeat region, and antiserum BR134 is
directed against the C terminus of tau. All three antisera recognize the
six adult human brain and three adult murine brain tau isoforms (Goe-
dert et al., 1989b; Go¨tz et al., 1995). T14 (a kind gift from Dr. V. M.-Y.
Lee, University of Pennsylvania, Philadelphia, PA) recognizes residues
141–149 of human tau (in the numbering of the longest human brain tau
isoform); it recognizes all human tau isoforms but fails to recognize
murine tau (Kosik et al., 1988). Antiserum MT1 was raised in white
Dutch rabbits using the synthetic peptide ARVASKDRTGNDEK (res-
idues 114–127 of the longest isoform of mouse brain tau) as the immuno-
gen. MT1 recognizes the three murine brain tau isoforms but fails to
recognize human tau. Alz-50 (a kind gift from Dr. P. Davies, Albert
Einstein College of Medicine, Bronx, NY) recognizes amino acids 5–15
and 312–322 of tau and is sensitive to the conformation of tau (Carmel
et al., 1996). BR133, BR134, BR135, Tau14, MT1, and Alz-50 are
phosphorylation-independent anti-tau antibodies. AT270 (Innogenetics,
Gent, Belgium) recognizes human and murine tau phosphorylated at
T181 (Goedert et al., 1994); AT8 (Innogenetics) recognizes human and
murine tau phosphorylated at S202 and T205 (Goedert et al., 1995);
AT100 (Innogenetics) recognizes human and murine tau phosphorylated
at T212 and S214 (Zheng-Fischho¨fer et al., 1998); pT212 (Biosource,
Camarillo, CA) recognizes human and murine tau phosphorylated at
T212 (Woods et al., 2001); CP3 (a kind gift from Dr. P. Davies) recog-
nizes human and murine tau phosphorylated at S214 (Jicha et al., 1999);
AT180 (Innogenetics) recognizes human and murine tau phosphorylated
at T231 (Goedert et al., 1994); 12E8 (a kind gift from Dr. P. Seubert, Elan
Pharmaceuticals, San Francisco, CA) recognizes human and murine tau
phosphorylated at S262 and/or S356 (Seubert et al., 1995); AD2 (a kind
gift from Dr. A. Delacourte, Institut National de la Sante´ et de la
Recherche Me´dicale U422, Lille, France) and PHF1 (a kind gift from Dr.
P. Davies) recognize human and murine tau phosphorylated at S396 and
S404 (Otvos et al., 1994; Bue´e-Scherrer et al., 1996); PG5 (a kind gift
from Dr. P. Davies) recognizes human and murine tau phosphorylated at
S409 (Jicha et al., 1999); AP422 recognizes human and murine tau
phosphorylated at S422 (Hasegawa et al., 1996). In addition to anti-tau
antibodies, tissue sections were also stained with a number of other
antibodies. They included antibodies to -amyloid (a kind gift from Dr.
V. M.-Y. Lee), parkin (Chemicon, Temecula, CA), ubiquitin (Dako,
Glostrup, Denmark, and Chemicon), the 20S proteasome (Affiniti, Re-
search Products, Exeter, UK), phospho-mitogen-activated protein
(MAP) kinase kinase 3/6 (Cell Signaling Technology, Beverly, MA),
phospho-MAP kinase (clone 12D4; Nanotools, Teningen, Germany), phos-
pho-p38 MAP kinase (Cell Signaling Technology), phospho-c-Jun N-
terminal protein kinase (JNK) (Cell Signaling Technology), phospho-
glycogen synthase kinase-3 (GSK3) (specific for phosphorylated Y279 of
GSK3 and phosphorylated Y216 of GSK3, clone 5G-2F; Upstate Bio-
technology, Lake Placid, NY), cyclin-dependent kinase 5 (cdk5) (Santa
Cruz Biotechnology, Santa Cruz, CA), the p35 activator of cdk5 (Santa
Cruz Biotechnology), Pin1 (N-19; Santa Cruz Biotechnology), active
caspase-3 (PharMingen, San Diego, CA, and Cell Signaling Technology),
cleaved -fodrin (Cell Signaling Technology), heparan sulfate (Seikagaku
Kogyo, Tokyo, Japan), heat shock protein 25 (Stressgen Biotechnologies,
Victoria, Canada), heat shock protein 70 (Stressgen Biotechnologies),
B-crystallin (Stressgen Biotechnologies), and glial fibrillary acidic protein
(GFAP; Dako).
Transgenic mice. Site-directed mutagenesis was used to introduce the
P301S mutation (using the numbering of the longest human brain tau
isoform) into the cDNA encoding the shortest human four-repeat tau
isoform (383 aa isoform of human tau). The mutated cDNA was subcloned
into a murine thy1.2 genomic expression vector (a kind gift from Dr. H. van
der Putten, Novartis, Basel, Switzerland) (Lu¨thi et al., 1997). This tau
expression construct was produced by subcloning P301S hTau43 cDNA into
a unique XhoI site of the expression vector. A Kozak consensus sequence
had been introduced upstream of the initiation codon. Vector sequences
were removed before microinjection. Transgenic mice were produced by
pronuclear injection of (C57BL/6J  CBA/ca) F1 embryos. Founders were
identified by PCR analysis of lysates from tail biopsies using the primer pair
5-GGTTTTTGCTGGAATCCTGG-3 and 5-GGAGTTCGAAGT-
GATGGAAG-3. Founder animals were intercrossed with C57BL/6J mice
to establish lines. Homozygosity was determined by matings with nontrans-
genic animals.
Immunoblot analysis. Brains and spinal cords from transgenic mice
were dounce homogenized in 2.5% (v/v) perchloric acid (0.5 ml/gm),
allowed to stand on ice for 20 min, and centrifuged for 10 min at
10,000  g. The supernatants were dialyzed against 50 mM Tris-HCl, pH
7.4, 1 mM dithiothreitol, and 0.1 mM phenylmethylsulfonyl fluoride
(PMSF) and used for immunoblot analysis, as described previously
(Goedert and Jakes, 1990). Comparison of the amount of expressed
soluble human tau with endogenous mouse tau was determined by
extracting brain and spinal cord samples from 5- to 6-month-old homozy-
gous transgenic mice. Tissues were homogenized in 5 vol of extraction
buffer (50 mM Tris-HCl, pH 7.4, 0.5 M NaCl, 0.1 mM PMSF, 1 g/ml
leupeptin, 1 g/ml pepstatin, 1 mM sodium orthovanadate, 50 mM sodium
fluoride, and 1 mM -glycerophosphate). After a 15 min centrifugation at
543,000  g, the supernatants were adjusted to 2% 2-mercaptoethanol,
boiled for 10 min, chilled on ice for 10 min, and centrifuged, and the
resulting supernatants were then brought to 50% ammonium sulfate.
After centrifugation at 543,000  g, the precipitates were resuspended in
50 mM Tris-HCl, pH 7.4, 0.1 mM PMSF, 1 g/ml leupeptin, and 1 g/ml
pepstatin. Dephosphorylation of tau with Escherichia coli alkaline phos-
phatase (Sigma, St. Louis, MO) was performed as described previously
(Goedert et al., 1992a). The relative tau levels were determined by
densitometry using purified recombinant tau proteins as standards. Var-
ious amounts of the final fractions were run on 10% SDS-PAGE along-
side recombinant human tau proteins and immunoblotted with anti-tau
serum BR134. The blots were developed using enhanced chemilumines-
cence (Amersham Biosciences, Arlington Heights, IL), and the bands
were scanned (Personal Densitometer SI; Molecular Dynamics, Sunny-
vale, CA) and analyzed using the IQMac version 1.2 software (Molecular
Dynamics). The readings given by the three mouse tau bands were added
together and compared with the reading given by the single human tau
band.
Histology and immunohistochemistry. Brain, spinal cord, and hindleg
muscle from P301S tau transgenic mice were analyzed histologically.
Animals were perfused transcardially with 4% paraformaldehyde in 0.1
M phosphate buffer, pH 7.2, and the tissues were postfixed for 2 hr.
Histological staining and immunohistochemistry were performed on
either 4 m sections obtained from paraffin-embedded tissue blocks or 30
m microtome sections. Thioflavin S staining and Bodian silver staining
were done as described previously (Yamamoto and Hirano, 1986). For
immunohistochemistry, sections were incubated overnight at 4°C with
Figure 1. Epitopes of anti-tau antibodies. A bar diagram of the 441 aa
isoform of human tau is shown, with the microtubule-binding repeat
region shown in black. Amino acids recognized by phosphorylation-
dependent antibodies are indicated above the bar diagram ( pS and pT ).
The epitopes of phosphorylation-independent antibodies are shown below
the bar diagram.
Allen et al. • Transgenic Mouse Model of Human Tauopathy J. Neurosci., November 1, 2002, 22(21):9340–9351 9341
the primary antibodies. Immunostaining was visualized using the avidin–
biotin system (Vectastain; Vector Laboratories, Burlingame, CA) and
3,3-diaminobenzidine (Sigma) as the chromogen. The sections were
counterstained with cresyl violet or hematoxylin and eosin. The colocal-
ization of activated MAP kinase family members and hyperphosphory-
lated tau was investigated by double-labeling immunofluorescence. Non-
specific binding sites were blocked by incubating free-floating brain and
spinal cord sections for 3 hr at room temperature with 3% bovine serum
albumin (BSA) and 0.1% saponin in PBS. The tissue sections were then
incubated overnight at room temperature with the following antibodies
in the presence of either the polyclonal anti-tau antibody BR134 or the
monoclonal antibody PHF1 (anti-phospho-MAP kinase kinase 3/6, anti-
activated MAP kinase, anti-phospho-JNK, and anti-phospho-p38). The
sections were washed five times in BSA/saponin/PBS and incubated with
anti-mouse IgG conjugated to Alexa-488 (Molecular Probes, Eugene,
OR) and anti-rabbit IgG conjugated to CY3 (Jackson ImmunoResearch,
West Grove, PA) for 3 hr at room temperature. For the colocalization of
Pin1 and hyperphosphorylated tau, tissue sections were subjected to
microwave irradiation for antigen retrieval, followed by the addition
of the polyclonal anti-Pin1 antibody and monoclonal antibody AT100.
Donkey anti-goat CY3 and donkey anti-mouse CY2 (Jackson Immuno-
Research) were used as secondary antibodies. After washing, sections
were mounted in Vectashield (Vector Laboratories) and imaged with a
Radiance 2100 confocal microscope (Bio-Rad, Hercules, CA).
Electron microscopy of tissue sections. Tissues were fixed in 4% para-
formaldehyde, postfixed in 1% osmium tetroxide, and embedded in
Epon. One-micrometer-thick sections were stained with toluidine blue.
Ultrathin sections were stained with uranyl acetate and lead citrate and
viewed with a Philips 300 electron microscope. For immunoelectron
microscopy, paraformaldehyde-fixed specimens (1 mm 3) were washed in
distilled water and placed in Tris-buffered saline, pH 7.6. Fifty-
micrometer-thick sections were cut using a vibratome. Immunogold
labeling with anti-tau antibody AT8 (1:5) was performed using 10 nm
gold particles (Goldmark Biologicals, Phillipsburg, NJ) conjugated to
goat anti-mouse IgG at a dilution of 1:10. Sections were postfixed in 2.5%
glutaraldehyde, followed by 1% osmium tetroxide, dehydrated through a
graded alcohol series, and embedded in epoxy resin. Semithin sections
were stained with toluidine blue. Ultrathin sections were contrasted with
lead citrate and uranyl acetate and scanned with the electron microscope.
Extraction and characterization of sarkosyl-insoluble tau. Sarkosyl-
insoluble tau was extracted from whole brains and spinal cords of
transgenic mice, as described for cerebral cortex from Alzheimer’s dis-
ease brains. The sarkosyl-insoluble material was analyzed by immuno-
blotting and electron microscopy. For immunoblotting, SDS-PAGE and
transfers were done, as described previously (Goedert and Jakes, 1990).
Dephosphorylation using E. coli alkaline phosphatase was performed as
described previously (Goedert et al., 1992a). For electron microscopy,
aliquots of the sarkosyl-insoluble material were placed on carbon-coated
400 mesh grids and stained with 1% lithium phosphotungstate. Micro-
graphs were recorded at a nominal magnification of 40,000 on a Philips
EM208S microscope, as described previously (Crowther, 1991). Proce-
dures for immunoelectron microscopy were as described previously
(Crowther, 1991).
Nerve cell counts. The numbers of nerve cells in lamina II (substantia
gelatinosa) and lamina IX (somatic motor neurons) of the lumbar spinal
cord were counted in three 6-month-old transgenic mice and three
age-matched controls. We used the atlas of Sidman et al. (1971) for the
macroscopic identification of lumbar segments L2–L3 and the micro-
scopic identification of laminas II and IX in cross sections. The widest
part of the lumbar enlargement (level L2–L3) was serially sectioned (8
m) and stained using hematoxylin and eosin, and laminas II and IX
were identified. A field of each section was digitally captured using a Spot
RT digital camera (Diagnostic Instruments, Sterling Heights, MI) at-
tached to a Leica (Wetzlar, Germany) FMLB microscope with a 10
objective. The areas of laminas II and IX were measured using supple-
mentary software of the digital camera. In each of the five serial sections
from each mouse, the number of nerve cells was counted manually using
a 20 or 40 objective. To avoid counting the same neuron in consec-
utive sections, only neurons with a nucleolus were included. The results
were expressed as the mean neuronal density (number of neurons per
millimeter square). Statistical analyses compared mean neuronal densi-
ties of control and transgenic mice. Hierarchical models were used which
made it possible to correlate the density measurements of the five
sections from each mouse (Goldstein, 1995). Individual mice were coded
as random effect and the type of mouse (control or transgenic) as fixed
effect.
Detection of apoptosis. The presence of DNA fragmentation in single
cells was investigated by in situ end-labeling (ISEL) of sections obtained
from paraffin-embedded tissue blocks, as described previously (Migheli
et al., 1997). Briefly, sections were pretreated with 0.5–5 g/ml protein-
ase K for 15 min at room temperature. They were then incubated with 20
U/ml terminal deoxynucleotidyl transferase (Roche Diagnostics, Indianap-
olis, IN) and 10 nmol/ml fluorescein-11-deoxyUTP (Roche Diagnostics)
for 2 hr at 37°C. The reaction product was revealed with peroxidase-
conjugated anti-fluorescein antibody (Roche Diagnostics) using diamino-
benzidine as the chromogen. For immunohistochemistry with antibodies
directed against activated caspase-3 and cleaved -fodrin, tissue sections
were subjected to microwave irradiation for antigen retrieval. They were
then incubated with 5% ovalbumin for 15 min, followed by a 15 min
incubation with 2% biotin. Immunohistochemistry was performed using
streptavidin–biotin and cobalt chloride-intensified diaminobenzidine or
3-amino-9-ethylcarbazole as substrate.
RESULTS
Production of transgenic mouse lines and
neurological phenotype
The neuron-specific elements of the mouse thy1 promoter were
used to produce transgenic mice expressing the shortest human
four-repeat tau isoform with the P301S mutation. Six founders
were obtained, five of which transmitted the transgene in a Men-
delian manner. Three of the five lines expressed high levels of
human tau protein in the brain and spinal cord and were used to
establish homozygous lines. The present report concentrates on
line 2541. At 5–6 months of age, homozygous animals from this
line developed a neurological phenotype that was characterized
by general muscle weakness, tremor, and a severe paraparesis.
When lifted by the tail, the mice were unable to extend their
hindlimbs. In most animals, an eye inflammation was also present.
Heterozygous animals developed a similar phenotype at 12–14
months of age.
Expression, phosphorylation, and solubility of mutant
human tau protein
By immunoblotting, a broad transgenic tau band of 52–58 kDa
apparent molecular mass was present in brains and spinal cords
from 5- to 6-month-old homozygous transgenic mice (Fig. 2A). It
was reactive with anti-tau serum BR134, which recognizes both
human and murine tau, and with antibody T14, which only rec-
ognizes human tau. The transgenic tau band was not immunore-
active with antibody MT1, which recognizes murine but not
human tau (data not shown). Dephosphorylation with alkaline
phosphatase was used to assess the expression level of transgenic
human tau relative to endogenous mouse tau (Fig. 2A). As shown
previously (Go¨tz et al., 1995; Kampers et al., 1999), dephospho-
rylated mouse brain tau runs as three bands that correspond to
the three tau isoforms with four repeats. In transgenic mice, an
additional human tau band of 52 kDa was observed that aligned
with the 383 aa isoform of recombinant human brain tau. In
brains and spinal cords from transgenic mice, human tau levels
were approximately twofold higher than the levels of total mouse
tau. The phosphorylation state of perchloric acid-soluble human
tau protein from mouse brain and spinal cord was investigated by
immunoblotting using 10 different phosphorylation-dependent
anti-tau antibodies (Fig. 2C). The human tau band was strongly
immunoreactive with antibodies AT270, AT8, pT212, AT180,
12E8, AD2, PG5, and AP422. No reactivity was observed with
antibodies AT100 or CP3.
Sarkosyl-insoluble tau protein was extracted from transgenic
mouse brain and spinal cord. A strong band of 64 kDa apparent
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molecular mass was detected by immunoblotting with antibody
T14 (Fig. 2B). After dephosphorylation, sarkosyl-insoluble tau
ran at 52 kDa and aligned with the recombinant 383 aa isoform of
human tau, as did dephosphorylated perchloric acid-soluble tau
(Fig. 2A,B). Sarkosyl-insoluble human tau protein was strongly
immunoreactive with all of the phosphorylation-dependent anti-
tau antibodies, including AT100 and CP3 (Fig. 2C).
Immunohistochemical and histochemical staining of
mutant human tau protein
The cellular distribution of tau protein was investigated in brains
and spinal cords from 5- to 6-month-old transgenic mice by using
phosphorylation-dependent and phosphorylation-independent
anti-tau antibodies (Figs. 3, 4; see Fig. 1 for antibody epitopes).
Strong labeling of nerve cell bodies and processes was observed in
most brain regions. For instance, in the cerebral cortex and the
hippocampal formation, numerous nerve cells were immunopo-
sitive (Figs. 3A,B, 4A). In frontal and temporal cortices, they
were concentrated in layers 2, 4, and 5. The largest number of
tau-immunoreactive nerve cells was present in the brainstem and
spinal cord. Figure 3 shows the staining in a number of regions
using the phosphorylation-dependent anti-tau antibody AT8.
Overall, the tau staining was either homogenous or had the
appearance of circumscribed inclusions. In some cells, particu-
larly in the cerebral cortex, it was distinctly granular.
Figure 2. Immunoblot analysis of tau protein in brains and spinal cords
from mice of the human P301S tau line. A, Perchloric acid-soluble tau was
extracted from the brain (B) and spinal cord (SC) of 5- to 6-month-old
mice and immunoblotted with anti-tau antibodies BR134 and T14 before
() and after () alkaline phosphatase treatment. Black arrowheads point
to the three mouse tau isoforms, with the white arrowhead pointing to the
single human tau isoform. B, Sarkosyl-insoluble tau was extracted from
brains (B) and spinal cords (SC) of 5- to 6-month-old transgenic mice and
immunoblotted with T14 before () and after () alkaline phosphatase
treatment. M, Mixture of the six recombinant human brain tau isoforms.
C, Reactivities of perchloric acid-soluble and sarkosyl-insoluble tau with
a panel of 10 different phosphorylation-dependent anti-tau antibodies.
Figure 3. Tau protein immunoreactivity in brains and spinal cords from
mice of the human P301S tau line. The phosphorylation-dependent anti-
tau antibody AT8 was used to stain the cerebral cortex (A, B), amygdala
(C), dentate nucleus of the cerebellum (D), brainstem (E, F ), and spinal
cord (G, H ). The transgenic mice used were 5 months old. Scale bars: A,
40 m (for A–C, E, F ); D, 60 m (for D, H ); G, 250 m.
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Immunoreactive nerve cells were observed with the phosphory-
lation-dependent anti-tau antibodies AT8, AT100, CP3, AT180,
12E8, PHF1, PG5, and AP422. Overall, the largest number of
stained cells was observed with AT8, followed by AP422, AT180,
and PG5. Fewer cells were labeled by AT100 and CP3, with the
smallest number of cells being stained by 12E8 and PHF1. Anti-
body AD2 gave a staining pattern similar to that seen for PHF1.
Regional differences were observed. For instance, strong and
widespread staining for 12E8 was present in the spinal cord but
not in the cerebral cortex. Staining with antibodies AP422, CP3,
12E8, AT180, and AT100 is illustrated in Figure 4. The
phosphorylation-independent, human-specific anti-tau antibody
T14 labeled numerous nerve cells (Fig. 4A,F), as did Alz-50,
BR133, and BR134. In contrast, antibody MT1, which is specific
for murine tau, gave only diffuse neuropil staining. Antibodies
directed against ubiquitin, parkin, the 20S proteasome, heparan
sulfate, heat shock protein 25, heat shock protein 70, B-
crystallin, cdk5, and the p35 activator of cdk5 failed to stain the
tau-positive cells. Most nerve cells were stained by the anti-
phospho-GSK3 antibody, regardless of whether they were immu-
noreactive for human tau. No staining for -amyloid was ob-
served. Sections of brain and spinal cord from transgenic mice
were also stained with the Bodian silver stain and thioflavin S.
Numerous nerve cells were silver positive (Fig. 4H) and fluores-
cent with thioflavin S (Fig. 5). The thioflavin S fluorescence was
weak (Fig. 5A–C) and resembled that given by the Pick bodies of
sporadic Pick’s disease (Fig. 5D).
Electron microscopy of tau filaments
Large numbers of abnormal filaments were observed in the cyto-
plasm and processes of nerve cells from 5- to 6-month-old trans-
genic mice. Representative sections of cerebral cortex, brainstem,
and spinal cord are shown in Figure 6. The filaments were
oriented randomly and were not membrane bound. Most fila-
ments appeared ribbon like, with approximate diameters of 5–15
nm. According to immunoelectron microscopy on tissue sections,
the filaments were strongly labeled by the phosphorylation-
dependent anti-tau antibody AT8 (Fig. 6C,D).
Isolated filaments were also characterized using sarkosyl-
insoluble preparations extracted from brains and spinal cords of
transgenic mice (Fig. 7). Labeling with antibodies against tau (see
Fig. 1 for antibody epitopes) revealed reasonably abundant tau-
containing filaments of rather irregular appearance but predom-
inantly of two morphologies (Fig. 7). The majority resembled
“half-twisted” ribbons, with an apparent width varying between 5
and 10 nm and with a very variable spacing between cross-overs.
A minority of filaments (Fig. 7 I,L) were more like Alzheimer-
paired helical filaments with a cross-over spacing of 70–80 nm.
The filaments were strongly labeled by phosphorylation-
independent antibodies BR133 and BR134, raised against the N-
and C-terminal regions of tau, but not by BR135, whose epitope
lies in the repeat region. They were also labeled by the human
tau-specific antibody T14. In contrast, only a small number of
filaments were labeled by the mouse tau-specific antibody MT1.
The filaments were not labeled by an anti-ubiquitin antibody. The
Figure 4. Tau protein immunoreactivity and silver staining in brains and
spinal cords from mice of the human P301S tau line. The human-specific,
phosphorylation-independent anti-tau antibody T14 was used to stain the
cerebral cortex (A) and spinal cord (F). The phosphorylation-dependent
anti-tau antibodies AP422 (B) and CP3 (C) were used to stain the cerebral
cortex. The phosphorylation-dependent anti-tau antibodies 12E8 (D) and
AT180 (E) were used to stain the brainstem. The phosphorylation-
dependent anti-tau antibody AT100 was used to stain the spinal cord (G).
Bodian silver staining of the amygdala is shown in H. The transgenic mice
used were 5 months old. Scale bars: A, 125 m (for A–D, G); E, 250 m; F,
100 m; H, 40 m.
Figure 5. Thioflavin S fluorescence in brains and spinal cords from mice
of the human P301S tau line. Amygdala (A), brainstem (B), and spinal
cord (C) from 6-month-old transgenic mice. D, Entorhinal cortex from a
case of Pick’s disease. Note the weak green fluorescence against a yellow-
ish–green background in A–C and the similarly weak fluorescence inten-
sity of Pick bodies against a green background in D. Some of the positive
cells in A–C are indicated by arrows, as are two positive Pick bodies in D.
Scale bar, 80 m.
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filaments were labeled by a range of phosphorylation-dependent
anti-tau antibodies but not 12E8, whose epitope lies in the repeat
region. Similar labeling patterns were found, where tested, for
filaments from brain and spinal cord.
Nerve cell numbers in the spinal cord
In ventral gray matter from 6-month-old homozygous human
P301S tau mice, a reduction in the number of motor neurons and
an increase in the number of glial cells were observed (Fig. 8A,B).
Neuronal cell bodies were often swollen or severely atrophic. In
some instances, pyknotic neurons were surrounded by glial cells,
suggestive of neuronophagia. Nerve cell counts showed a 49%
reduction in the number of motor neurons in the anterior horn of
the spinal cord from transgenic mice compared with age-matched
controls (Fig. 8C). Occasional severely atrophic neurons may not
have been counted, because they lacked a visible nucleolus. The
estimated mean was 8.14/mm2 in control mice and 4.02/mm2 in
Figure 6. Electron microscopy and immunoelectron microscopy of nerve cells in brains and spinal cords from mice of the human P301S tau line. A, B,
Cerebral cortex; C, D, brainstem; E, F, spinal cord. B, D, F, Higher magnifications of parts of the cytoplasmic regions from A, C, and E. Note the large
numbers of abnormal filaments in the cytoplasm and apical dendrite. The electron micrographs in C and D show immunogold labeling of filaments using
the phosphorylation-dependent anti-tau antibody AT8. Scale bars: C, 1.5 m; E, 5.5 m (for A, E); F, 300 nm (for B, D, F ).
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transgenic mice ( p  0.0001), with an estimated difference of
4.12/mm2 (95% confidence interval of 2.8–5.4). In contrast, the
neuronal density in the substantia gelatinosa was not significantly
different between control and transgenic mice ( p  0.7). The
respective estimated means were 502.6 and 494.3, with an esti-
mated difference of 8.3/mm2 (95% confidence interval of 38.3
to 54.9). The reduction in the number of motor neurons was
accompanied by a reactive astrocytosis, as detected by a marked
increase in GFAP staining (Fig. 9A,B). In hindlimb skeletal
muscle from transgenic mice, groups of atrophic, angulated mus-
cle fibers were frequently observed amid normal-looking fibers,
indicative of denervation atrophy (Fig. 9C).
Staining with apoptosis markers
Apoptotic profiles, as identified by ISEL and immunoreactivity of
activated caspase-3 and cleaved -fodrin, were extremely rare or
absent in brains and spinal cords from 5- to 6-month-old trans-
genic mice. (Fig. 10A,C,E). The number of caspase-3-positive
cells never exceeded one or two in the entire brain. These cells,
which were found at the same frequency in brains from control
mice, were located primarily in the cerebral cortex and hippocam-
pus. Brain sections from 8-d-old citron kinase/ mice (Di Cunto
et al., 2000) and 1-d-old control mice were used as positive
controls. They showed apoptotic cells in the external granular
layer of the cerebellum (Fig. 10B,D,F).
Staining of activated MAP kinase family members and
the prolyl isomerase Pin1
The colocalization of activated MAP kinase family members and
hyperphosphorylated tau was investigated by double labeling im-
munofluorescence in brains and spinal cords from 5- to 6-month-
old transgenic mice. Antibodies specific for activated MAP ki-
nase, phospho-JNK, and phospho-p38 labeled the nerve cells that
were tau positive (Fig. 11A–F). The same was true of an antibody
specific for phospho-MAP kinase kinase 3/6, the upstream acti-
vator of the p38 MAP kinase family (data not shown). The
observed staining did not result from a cross-reaction with hyper-
phosphorylated tau, because the phosphorylation-dependent pro-
tein kinase antibodies failed to recognize the sarkosyl-insoluble
64 kDa tau band from brains and spinal cords of transgenic mice
(data not shown). By immunoblotting, the antibody specific for
phospho-p38 MAP kinase did not distinguish between p38/
stress-activated protein kinase (SAPK)2a, p38/SAPK2b, p38/
SAPK3, and p38/SAPK4 (data not shown). Staining of the prolyl
isomerase Pin1 was only observed in a small minority (1%) of
AT100-positive cells in the cerebral cortex, in which some cyto-
plasmic granules were immunoreactive (Fig. 11G,H). Pin1 stain-
ing was not seen in other brain regions or in the spinal cord.
DISCUSSION
We describe a transgenic mouse line that expresses in nerve cells
four-repeat human tau protein with the P301S mutation. At 5–6
months of age, homozygous animals developed a neurological
phenotype dominated by a severe paraparesis. By light micros-
copy, nerve cells in the brain and spinal cord were strongly
immunoreactive for hyperphosphorylated human tau but not for
mouse tau. Many nerve cells were also strongly silver positive and
weakly fluorescent for thioflavin S. The largest number of tau-
positive nerve cells was present in the brainstem and spinal cord.
Numerous positive cells were also observed in other brain re-
gions, including the cerebral cortex and hippocampus.
Figure 7. Immunoelectron microscopy of
isolated filaments prepared by sarkosyl ex-
traction of brains and spinal cords from mice
of the human P301S tau line. A–E, Phospho-
rylation-independent anti-tau antibodies; F,
anti-ubiquitin antibody (Ub); G–L, phospho-
rylation-dependent anti-tau antibodies. In
each case, the antibody is named above the
panel. The filaments in C and G came from
spinal cord, the rest from brain. Antibodies
BR135, Ub, and 12E8 did not label the fila-
ments. Most filaments resembled half-
twisted ribbons (A–H, J, K ), whereas some
filaments were reminiscent of paired helical
filaments (I, L). The transgenic mice used
were 5–6 months old. Scale bar, 100 nm.
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By electron microscopy on tissue sections, abundant filaments
made of hyperphosphorylated tau protein were detected through-
out the brain and in the spinal cord. The majority of filaments
resembled the half-twisted ribbons described previously in some
cases of FTDP-17 (Spillantini et al., 1998b; Mirra et al., 1999;
Rizzini et al., 2000; Neumann et al., 2001). A minority of fila-
ments were reminiscent of the paired helical filaments of Alzhei-
mer’s disease. Isolated filaments were decorated by antibodies
directed against the N and C termini of tau but not by BR135, an
antibody specific for the microtubule-binding repeat region, indi-
cating that the repeat region of tau forms part of the core of the
filaments. Identical findings have been reported previously for
synthetic tau filaments (Goedert et al., 1996) and for filaments
isolated from Alzheimer’s disease and FTDP-17 brains (Goedert
et al., 1992a, 1994; Hasegawa et al., 1996; Spillantini et al., 1997).
Isolated filaments from transgenic mouse brain and spinal cord
were made of mutant human tau and decorated by a large number
of phosphorylation-dependent anti-tau antibodies. The one ex-
ception was antibody 12E8, whose epitope lies in the repeat
region (Seubert et al., 1995) and was therefore inaccessible in the
Figure 8. Nerve cell loss in spinal cords from mice of the human P301S
tau line. A, B, Hematoxylin and eosin-stained sections of the ventral gray
matter of the spinal cord (level L2–L3) from a 6-month-old control mouse
(A) and a transgenic mouse (B) of the same age. Swollen, abnormal
material-containing motor neurons are indicated by arrows. Arrowheads
point to atrophic motor neurons, with dashed arrows pointing to pyknotic
cells that are surrounded by glial cells, suggestive of neuronophagia. C,
Graph showing the density of motor neurons (expressed as number of
neurons per millimeter square) in the anterior horn of the lumbar spinal
cord from 6-month-old control and human P301S tau transgenic mice.
Nerve cell numbers were determined in five consecutive sections from
each animal, with the density of motor neurons from each section being
represented by a circle. The results are expressed as the means  SEM
(n 	 3); *p  0.0001. Scale bar: A, 60 m (for A, B).
Figure 9. Astrocytosis in the spinal cord and denervation atrophy in
skeletal muscle from mice of the human P301S tau line. A, B, The ventral
gray matter of the spinal cord (level L2–L3) from a 6-month-old control
mouse ( A) and a transgenic mouse ( B) of the same age was stained with
an anti-glial fibrillary acidic protein antibody. Note the weak immunore-
activity in A and the much stronger staining in B, as reflected in a large
number of immunopositive astrocytic cell bodies and coarse processes. C,
Hindlimb skeletal muscle from a transgenic mouse was stained with
toluidine blue. Groups of atrophic, angulated muscle fibers are indicated
by arrows. Scale bars: A, 50 m (for A, B); C, 60 m.
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intact filaments. Isolated tau filaments were not decorated by
anti-ubiquitin antibodies, which also failed to stain tissue sections
from transgenic mice. This is consistent with previous findings
which demonstrated that the ubiquitination of tau in Alzheimer’s
disease occurs after filament assembly (Goedert et al., 1992a;
Morishima-Kawashima et al., 1993).
The morphological findings were mirrored at the biochemical
level. Sarkosyl-insoluble tau from transgenic mouse brain and
spinal cord ran as a hyperphosphorylated 64 kDa band that was
labeled by all anti-human tau antibodies tested, including BR135
and 12E8. However, this band was not labeled by antibody MT1.
In human tauopathies, the 383 aa tau isoform also runs as a
hyperphosphorylated 64 kDa band (Goedert et al., 1992a; Mulot
et al., 1994). The biochemical and morphological characteristics
of sarkosyl-insoluble tau from the transgenic mice were therefore
identical to those observed in human tauopathies. Abundant tau
filaments have also been described in sections of brainstems and
spinal cords from mice transgenic for human P301L tau (Lewis et
al., 2000) but not in other mouse lines transgenic for human tau
mutants (Go¨tz et al., 2001a,b; Lim et al., 2001; Tanemura et al.,
2001, 2002). Unlike the present findings, tau inclusions were
ubiquitin positive by light microscopy. The characteristics of
isolated tau filaments were not reported (Lewis et al., 2000).
Perchloric acid-soluble tau from transgenic mouse brain and
spinal cord ran as a broad band of 52–58 kDa that was immuno-
reactive with all phosphorylation-dependent anti-tau antibodies,
except AT100 and CP3. In conjunction with our previous work
(Probst et al., 2000), this provides the first demonstration of the
existence of a pool of soluble tau protein phosphorylated at many
but not all sites before filament assembly. It also indicates that
immunoreactivity for phospho-S214 closely mirrors the presence
of filaments, suggesting that phosphorylation of this site occurs
after filament assembly. In transgenic mice, AT100 stained only a
subset of the nerve cells that were immunoreactive with other
antibodies, such as T14 or AT8, indicating that only this subset of
nerve cells contained tau filaments.
Neurodegeneration was present in the spinal cord of 6-month-
old transgenic mice, as indicated by a 49% reduction in the
number of motor neurons. Both abnormally enlarged and severely
atrophic motor neurons were observed. In some instances, the
latter were surrounded by glial cells, suggestive of neuronophagia.
Moreover, astrocytosis in spinal cord and denervation atrophy in
skeletal muscle were in evidence. It remains to be determined
whether nerve cells were also lost in the brain. In the spinal cord,
tau filament formation thus correlated with nerve cell death. The
same is true of nerve cells in the human tauopathies (Lee et al.,
2001). A similar loss in the number of motor neurons was also
reported in transgenic mice from the human P301L tau line with
filaments (Lewis et al., 2000). In mice transgenic for wild-type
human tau, no tau filaments or nerve cell loss was observed
(Ishihara et al., 1999; Spittaels et al., 1999; Probst et al., 2000). In
contrast, in Drosophila melanogaster expressing either wild-type
or mutant human tau, nerve cell death by apoptosis was found in
the apparent absence of tau filaments (Wittmann et al., 2001;
Jackson et al., 2002).
In the human P301S tau line, no evidence for apoptosis was
obtained when DNA fragmentation and staining for activated
caspase-3 and cleaved -fodrin were studied. This is in contrast to
mice transgenic for human P301L tau, where the presence of
terminal deoxynucleotidyl transferase-mediated biotinylated
UTP nick end labeling-positive nerve cells was reported (Go¨tz et
al., 2001a; Ho et al., 2001). However, the present findings are in
line with work on the human tauopathies, where DNA fragmen-
tation and staining for activated caspase-3 were not detected
(Migheli et al., 1994; Atzori et al., 2001; Ferrer et al., 2001a).
In human diseases, tau inclusions are known to colocalize with
activated MAP kinase family members, in particular, SAPKs
(Hensley et al., 1999; Perry et al., 1999; Zhu et al., 2000; Atzori
et al., 2001; Ferrer et al., 2001a,b). Similar results were obtained
in the human P301S tau line, where activated MAP kinase, JNK,
and p38 colocalized with hyperphosphorylated tau. The same was
not true of other protein kinases, such as GSK3 and cdk5. MAP
kinase and SAPKs phosphorylate tau at many sites in vitro
(Drewes et al., 1992; Goedert et al., 1992b, 1997; Reynolds et al.,
1997), suggesting that they may be involved in the hyperphospho-
rylation of tau and that specific inhibitors of these enzymes
(Cohen, 2002) might be therapeutically beneficial. It remains to
be determined whether activation of MAP kinase and SAPKs
precedes the assembly of tau into filaments. Staining for activated
MAP kinase family members was not observed in the transgenic
mouse line ALZ17 (Probst et al., 2000), which expresses wild-
type human tau protein but does not develop abundant tau
filaments (our unpublished observations).
Activation of SAPKs is likely to have additional effects. Both
JNK and p38 have been linked to the induction of apoptosis (Xia
et al., 1995), although their effects are strongly cell and context
dependent (Chang and Karin, 2001). The present findings, to-
gether with recent work on the human tauopathies (Atzori et al.,
2001), indicate that in diseases with a filamentous tau pathology,
SAPKs do not activate or regulate an apoptotic cascade. Like
MAP kinase family members, the prolyl isomerase Pin1 has been
Figure 10. ISEL, staining of activated caspase-3, and staining of cleaved
-fodrin in spinal cords from mice of the human P301S tau line. A, B,
ISEL; C, D, staining of activated caspase-3; E, F, staining of cleaved
-fodrin. The sections in A, C, and E are from spinal cords of 6-month-old
human P301S tau transgenic mice. The sections in B and D are from the
cerebellum of 8-d-old citron kinase/ mice, and the section in F is from
the cerebellum of a 1-d-old control mouse. No specific reaction product is
seen in A, C, and E. Some of the immunopositive cells in B, D, and F are
indicated by arrows. Scale bar: F, 50 m (for A–F ).
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reported to colocalize with filamentous tau deposits in Alzhei-
mer’s disease brain (Lu et al., 1999). It was proposed that this may
contribute to nerve cell death through a reduction in the level of
functional Pin1. However, in the mouse line expressing human
P301S tau, Pin1 was only present in a small minority of tau-
positive nerve cells in the cerebral cortex, where it localized to
cytoplasmic granules.
In conclusion, the transgenic mouse line described here exhibits
the essential features of a human tauopathy, including the forma-
tion of abundant filaments made of hyperphosphorylated tau
protein and nerve cell degeneration. Although in human cases
with the P301S mutation in Tau, both nerve and glial cells in the
brain are affected (Bugiani et al., 1999), in the mouse line, tau
deposits are seen only in nerve cells. The transgenic mice do not
exhibit the selective pattern of nerve cell degeneration character-
istic of the human tauopathy, because they show spinal cord as
well as widespread brain pathology. These differences in selec-
tivity between mouse model and human disease may have re-
sulted from our use of the murine thy1 promoter to drive expres-
sion of mutant human tau, the expression of a single isoform of
mutant human tau protein on a wild-type mouse tau background,
or a different neuronal vulnerability to mutant human tau in mice
and humans. This notwithstanding, the mouse line expressing
human P301S tau will be of great value for a better understanding
of the molecular mechanisms by which mutant tau protein causes
the dysfunction and death of nerve cells. It may for instance help
to establish whether hyperphosphorylation of tau leads to fila-
ment assembly and whether the accumulation of tau filaments
results in the demise of nerve cells. This may in turn lead to the
design of new therapeutic strategies aimed at preventing tau
dysfunction.
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